Graph neural networks
Can a neural network predict which cancer drugs work on which cells?
Open access · cc by · source: Europe PMC
Combining a graph network for drug structure with gene features predicts drug sensitivity well on familiar cell lines, but error more than doubles on cell lines never seen in training.
Study at a glance
- Design
- Computational / modelling — Deep model combining a GNN over drug molecular graphs with a 1D-CNN gene branch, trained on cancer cell-line screens with ablations
- N
- N=177128 · Drug–cell-line instances in the processed GDSC dataset (plus a smaller CCLE dataset of 10853 instances)
- Population
- Cancer cell lines screened with anticancer drugs (GDSC and CCLE)
- Outcome
- Mean squared error and R-squared for predicted log IC50
Structured fields used in claim comparison tables when every cited study has a complete layer.
Key findings
The best model, using multiple gene weight layers plus self-attention, reached an MSE of 0.9384 and R-squared of 0.8583 on the random split and beat earlier published methods. Simply adding mutation data to expression made results slightly worse, while a learned gene weight layer combined them better. When whole cell lines were held out, MSE rose to 2.2793, showing much weaker generalisation to new cell lines.
Methodology
The authors built SWnet, which encodes each drug's molecular graph with a graph neural network and each cell line's gene expression and mutations with a convolutional branch, then merges them to predict drug sensitivity (log IC50). They trained and tested it on large cancer cell-line screening datasets using a random 90/10 split. They ran ablations on how mutations are combined, multi-task gene weight layers, self-attention over drug similarity, and graph radius, and finally tested a split where whole cell lines were held out.
Limitations
The headline accuracy comes from a random split where the same cell lines and drugs appear in both training and test data, which overstates performance on truly new cases. Results are on in-vitro cell lines, not patients, so clinical usefulness is untested. Comparisons with prior methods rely on reported numbers rather than a single controlled re-run, and the authors note the model is hard to train on small datasets. The biological interpretation of gene weights is suggestive, based on protein interaction networks, not experimental validation.
How this study connects
Role on claims
Each row is a claim on a concept or method page where this paper supports, challenges, or qualifies the statement. Roles are hand-checked — not a model guess.
GNN-based drug-response models did well on random splits but much worse on held-out cell lines (SWnet MSE rose from 0.94 to 2.28).
Evidence for the claim as stated.
Open questions
Tensions this paper is part of
From concept pages' “where studies disagree.” Disagreement means the same question; scope means different assays, populations, or outcomes.
GNN-based drug-response models did well on random splits but much worse on held-out cell lines (SWnet MSE rose from 0.94 to 2.28).
Related papers in this topic
Same topic cluster — not a recommendation engine.
- Can spreading signals through a protein network find disease genes?
- Can a known gene network make microarray classifiers interpretable?
- Can a graph neural network sort unknown phage DNA into families?
- Can self-supervised learning predict how mutations change binding?
- Does letting each node choose its own depth fix GNN over-smoothing?